Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S, Itabe H, Takano T
Second Department of Pathology, School of Medicine, Fukuoka University, Japan.
Atherosclerosis. 1998 Nov;141(1):61-75. doi: 10.1016/s0021-9150(98)00149-x.
To better understand the role of advanced glycation end products (AGEs) in atherogenesis, we developed specific antibodies against different immunological epitopes of AGE structures, including Nepsilon-(carboxymethyl)lysine-protein adduct (CML) and a structure(s) other than CML (nonCML), and demonstrated the immunohistochemical localization of CML- and nonCML-epitopes in atherosclerotic lesions of human aorta, which were obtained at autopsy from 20 nondiabetic patients (12 males and eight females; mean age, 60.8+/-16.7 years). Monoclonal anti-CML antibody (6D12) recognized not only AGE-modified proteins, but also CML-modified proteins. On the other hand, polyclonal anti-nonCML antibody reacted to AGE-modified proteins, but not to CML-modified proteins. Both antibodies were unreactive to the early-stage products of glycation, including fructose-modified butyloxycarbonyl-lysine and fructose-epsilon-aminocaproic acid. Atherosclerotic lesions included diffuse intimal thickening (DIT), fatty streaks (FS), atherosclerotic plaques (AP) and complicated lesions. An immunohistochemical analysis showed both CML- and nonCML-epitopes to be found along the collagen fibers in DIT in subjects more than 40 years old, but not in subjects less than 40 years old. CML-epitopes accumulated mainly in the cytoplasm of macrophage/foam cells, while nonCML-epitopes accumulated exclusively in the extracellular spaces in FS. APs showed the CML-epitope stored macrophage/foam cells, and the accumulation of both CML- and nonCML-epitopes in the lipid-rich fibrous area. An immunohistochemical analysis with a monoclonal antibody against oxidized low density lipoprotein (FOH1a/DLH3) showed the presence of this antigen within the cytoplasm of the macrophage/foam cells in atherosclerotic lesions, which were also positive for the CML-epitopes. These findings thus suggest that the heterogeneous localization of AGEs in atherosclerotic lesions depends on their different epitopes, and that a close link, therefore, exists between the peroxidation of LDL and the formation of AGEs in atherosclerotic lesions.
为了更好地理解晚期糖基化终产物(AGEs)在动脉粥样硬化形成中的作用,我们开发了针对AGE结构不同免疫表位的特异性抗体,包括Nε-(羧甲基)赖氨酸-蛋白质加合物(CML)和CML以外的一种或多种结构(非CML),并在20例非糖尿病患者(12例男性和8例女性;平均年龄60.8±16.7岁)尸检获取的人主动脉粥样硬化病变中证实了CML和非CML表位的免疫组织化学定位。单克隆抗CML抗体(6D12)不仅识别AGE修饰的蛋白质,还识别CML修饰的蛋白质。另一方面,多克隆抗非CML抗体与AGE修饰的蛋白质反应,但不与CML修饰的蛋白质反应。两种抗体对糖基化的早期产物均无反应,包括果糖修饰的丁氧羰基赖氨酸和果糖-ε-氨基己酸。动脉粥样硬化病变包括弥漫性内膜增厚(DIT)、脂纹(FS)、动脉粥样硬化斑块(AP)和复杂病变。免疫组织化学分析显示,40岁以上受试者的DIT中,CML和非CML表位均沿胶原纤维分布,但40岁以下受试者中未发现。CML表位主要积聚在巨噬细胞/泡沫细胞的细胞质中,而非CML表位仅积聚在FS的细胞外间隙中。AP显示CML表位储存在巨噬细胞/泡沫细胞中,且CML和非CML表位均积聚在富含脂质的纤维区域。用抗氧化低密度脂蛋白单克隆抗体(FOH1a/DLH3)进行的免疫组织化学分析显示,该抗原存在于动脉粥样硬化病变巨噬细胞/泡沫细胞的细胞质中,这些细胞对CML表位也呈阳性。因此,这些发现表明,AGEs在动脉粥样硬化病变中的异质定位取决于它们不同的表位,因此,在动脉粥样硬化病变中,低密度脂蛋白的过氧化与AGEs的形成之间存在密切联系。